Background pattern
HEPCLUDEX 2 mg POWDER FOR INJECTABLE SOLUTION

HEPCLUDEX 2 mg POWDER FOR INJECTABLE SOLUTION

Ask a doctor about a prescription for HEPCLUDEX 2 mg POWDER FOR INJECTABLE SOLUTION

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use HEPCLUDEX 2 mg POWDER FOR INJECTABLE SOLUTION

Introduction

Package Leaflet: Information for the Patient

Hepcludex 2 mg powder for solution for injection

bulevirtide

This medicinal product is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects you may get. The last section of the leaflet contains information on how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What Hepcludex is and what it is used for
  2. What you need to know before you use Hepcludex
  3. How to use Hepcludex
  4. Possible side effects
  5. Storage of Hepcludex
  6. Contents of the pack and other information
  7. Step-by-step injection guide

1. What Hepcludex is and what it is used for

What Hepcludex is

Hepcludex contains the active substance bulevirtide, which is an antiviral medicine.

What Hepcludex is used for

Hepcludex is used to treat long-term (chronic) infection with the hepatitis delta virus (HDV) in adults with compensated liver disease (when the liver is still working properly). Hepatitis delta virus infection causes liver inflammation.

How Hepcludex works

HDV uses a specific protein from liver cells to enter these cells. Bulevirtide, the active substance in this medicine, blocks the protein and thus prevents HDV from entering liver cells. This reduces the spread of HDV in the liver and reduces inflammation.

2. What you need to know before you use Hepcludex

Do not use Hepcludex:

  1. if you are allergic to bulevirtide or any of the other ingredients of this medicine (listed in section 6).

If you are unsure, consult your doctor before taking this medicine.

Warnings and precautions

Do not stop treatment with Hepcludex unless your doctor advises you to do so. Stopping treatment may reactivate the infection and worsen your disease.

Consult your doctor or pharmacist before starting treatment with Hepcludex:

  1. if your liver is not working properly – it is not known how Hepcludex works in these circumstances; if your liver is not working well, it is not recommended to use Hepcludex.
  1. if you have had kidney disease or if blood tests show kidney problems. Before and during treatment, your doctor may ask for blood tests to check that your kidneys are working properly;
  1. if you have HIV or hepatitis C infection - it is not known how Hepcludex works in these circumstances; your doctor may ask for blood tests to check the status of your HIV or hepatitis C infection.

Children and adolescents

Children and adolescents under 18 years of age should not be treated with Hepcludex.

Other medicines and Hepcludex

Tell your doctor if you are using, have recently used or might use any other medicines.

Some medicines may increase the side effects of Hepcludex and should not be taken at the same time. This is why you should tell your doctor if you are taking any of these medicines:

  1. ciclosporin, a medicine that suppresses the immune system;
  2. ezetimibe, used to treat high blood cholesterol levels;
  3. irbesartan, used to treat high blood pressure and heart disease;
  4. ritonavir, used to treat HIV infection;
  5. sulfasalazine, used to treat rheumatoid arthritis, ulcerative colitis and Crohn's disease.

Some medicines may increase or decrease the effects of Hepcludex when taken together. In some cases, you may need to have some tests or your doctor may need to change the dose or monitor you regularly:

  1. cancer treatments (e.g. dasatinib, docetaxel, ibrutinib or paclitaxel);
  2. antihistamines used for allergies (e.g. ebastine or fexofenadine);
  3. medicines for the immune system (e.g. everolimus, sirolimus or tacrolimus);
  4. medicines for the treatment of hepatitis C and HIV (e.g. darunavir, glecaprevir, grazoprevir, indinavir, maraviroc, paritaprevir, saquinavir, simeprevir, tipranavir or voxilaprevir);
  5. medicines for diabetes (e.g. glibenclamide, nateglinide or repaglinide);
  6. medicines for erectile dysfunction (e.g. avanafil, sildenafil or vardenafil);
  7. medicines for the treatment of high blood pressure and heart disease (e.g. olmesartan, telmisartan or valsartan);
  8. statins, medicines used for high blood cholesterol levels (e.g. atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin or simvastatin);
  9. thyroid hormones used to treat thyroid problems;
  10. alfentanil, an opioid medicine used to treat severe pain;
  11. bosentan, used for pulmonary arterial hypertension;
  12. buspirone, a medicine for anxiety;
  13. budesonide, used for asthma and chronic obstructive pulmonary disease;
  14. conivaptan and tolvaptan, used to treat hyponatraemia (low sodium levels);
  15. darifenacin, used to treat urinary incontinence;
  16. dronedarone, a medicine for cardiac arrhythmias;
  17. eletriptan, used for migraine headaches;
  18. eplerenone, used for hypertension;
  19. estra-3-sulfate, a hormonal medicine for menopause;
  20. felodipine and nisoldipine (heart medicines);
  21. lomitapide, used for high blood cholesterol levels;
  22. lurasidone and quetiapine, antipsychotic medicines for psychiatric disorders;
  23. midazolam and triazolam, medicines for insomnia (inability to sleep) and for anaesthesia (to prevent pain during surgery);
  24. naloxegol, used to treat opioid dependence for severe pain;
  25. ticagrelor, an anticoagulant to prevent blood clotting.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. You should not use this medicine unless your doctor specifically advises you to do so.

If you are a woman of childbearing potential, you should not use this medicine without using an effective method of contraception.

Talk to your doctor to decide whether you can breast-feed during treatment with Hepcludex. It is not known whether Hepcludex is excreted in breast milk. Therefore, a decision must be made whether to discontinue breast-feeding or to discontinue Hepcludex treatment.

Driving and using machines

Dizziness and fatigue are side effects that may affect your ability to drive and use machines. If you are unsure, consult your doctor.

Hepcludex contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per ml, which is essentially ‘sodium-free’.

3. How to use Hepcludex

Follow the instructions for administration of this medicine exactly as advised by your doctor. If you are unsure, consult your doctor again.

Dosage

The recommended dose is 2 mg once daily by subcutaneous injection (just under the skin). Your doctor will tell you how long you should use the medicine.

Your doctor and nurse will teach you how to prepare and inject Hepcludex. This leaflet contains a step-by-step injection guide to help you inject the medicine (see section 7).

If you use more Hepcludex than you should

The usual dose is 2 mg (1 vial) per day. If you think you may have received more than you should, tell your doctor immediately.

If you forget to use Hepcludex

If it has been less than 4 hours since you missed a dose of Hepcludex, you should inject the missed dose as soon as possible and administer the next scheduled dose at the usual time.

If it has been more than 4 hours since you missed a dose of Hepcludex, do not inject the missed dose. You should administer the next dose the following day at the usual time. Do not inject a double dose to make up for a missed dose. Inform your doctor if you have missed a dose of Hepcludex.

If you stop treatment with Hepcludex

If you no longer wish to continue using Hepcludex, consult your doctor before stopping treatment. Stopping treatment may reactivate the infection and worsen your disease. Inform your doctor immediately about any change in symptoms after stopping treatment.

If you have any further questions on the use of Hepcludex, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you experience any side effect or if you notice any side effect not mentioned in this leaflet, consult your doctor.

The following side effect is very common(may affect more than 1 in 10 people):

  • headache.

The following side effects are common(may affect up to 1 in 10 people):

  • dizziness
  • nausea
  • fatigue
  • flu-like illness
  • itching
  • joint pain
  • injection site reactions which may include swelling, redness, irritation, bruising, itching, rash, induration, infection or pain at the injection site.

The following side effects are uncommon(may affect up to 1 in 100 people):

  • allergic reactions, including anaphylactic reaction (a life-threatening allergic reaction).

Symptoms of allergic reactions may include:

  • shortness of breath or wheezing
  • swelling of the face, lips, tongue or throat (angioedema)
  • skin rash
  • changes in blood pressure or heart rate.

Symptoms of an anaphylactic reaction are the same as those of an allergic reaction, but are more severe and require immediate medical attention.

Blood tests may also show:

  • increased bile acids in the blood (very common)
  • increased white blood cells (eosinophils) (common).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Hepcludex

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial after ‘EXP’. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C to 8°C). To protect from light, keep the vials in the outer carton.

The reconstituted solution should be used immediately. However, if this is not possible, it can be stored for a maximum of 2 hours at a temperature of up to 25°C.

Medicines or needles should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines or needles no longer required.

6. Container Contents and Additional Information

Hepcludex Composition

The active ingredient is bulevirtida 2 mg. Each vial contains bulevirtida acetate equivalent to 2 mg of bulevirtida.

The other components are sodium carbonate anhydrous, sodium hydrogen carbonate, mannitol, hydrochloric acid, and sodium hydroxide.

Product Appearance and Container Contents

Bulevirtida is a powder for solution for injection and is presented as a white or off-white powder.

Each box contains 30 individual doses.

Marketing Authorization Holder

Gilead Sciences Ireland UC

Carrigtohill

County Cork, T45 DP77

Ireland

Manufacturer

LYOCONTRACT GmbH

Pulverwiese 1

38871 Ilsenburg

Germany

or

Gilead Sciences Ireland UC

IDA Business and Technology Park

Carrigtohill

Co. Cork

Ireland

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

België/Belgique/Belgien

Gilead Sciences Belgium SRL-BV

Tel: + 32 (0) 24 01 35 50

Lietuva

Gilead Sciences Poland Sp. z o.o.

Tel.: + 48 (0) 22 262 8702

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Luxembourg/Luxemburg

Gilead Sciences Belgium SRL-BV

Tel: + 32 (0) 24 01 35 50

Ceská republika

Gilead Sciences s.r.o.

Tel: + 420 (0) 910 871 986

Magyarország

Gilead Sciences Ireland UC

Tel.: + 353 (0) 1 686 1888

Danmark

Gilead Sciences Sweden AB

Tlf: + 46 (0) 8 5057 1849

Malta

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Deutschland

Gilead Sciences GmbH

Tel: + 49 (0) 89 899890-0

Nederland

Gilead Sciences Netherlands B.V.

Tel: + 31 (0) 20 718 36 98

Eesti

Gilead Sciences Poland Sp. z o.o.

Tel.: +48 (0) 22 262 8702

Norge

Gilead Sciences Sweden AB

Tlf: + 46 (0) 8 5057 1849

Ελλáδα

Gilead Sciences Ελλáς Μ.ΕΠΕ.

Τηλ: + 30 (0) 210 8930 100

Österreich

Gilead Sciences GesmbH

Tel: + 43 (0) 1 260 830

España

Gilead Sciences, S.L.

Tel: + 34 (0) 91 378 98 30

Polska

Gilead Sciences Poland Sp. z o.o.

Tel.: + 48 (0) 22 262 8702

France

Gilead Sciences

Tél: + 33 (0) 1 46 09 41 00

Portugal

Gilead Sciences, Lda.

Tel: + 351 (0) 21 7928790

Hrvatska

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

România

Gilead Sciences (GSR) S.R.L.

Tel: +40 31 631 18 00

Ireland

Gilead Sciences Ireland UC

Tel: + 353 (0) 214 825 999

Slovenija

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Ísland

Gilead Sciences Sweden AB

Sími: + 46 (0) 8 5057 1849

Slovenská republika

Gilead Sciences Slovakia s.r.o.

Tel: + 421 (0) 232 121 210

Italia

Gilead Sciences S.r.l.

Tel: + 39 02 439201

Suomi/Finland

Gilead Sciences Sweden AB

Puh/Tel: + 46 (0) 8 5057 1849

Κúπρος

Gilead Sciences Ελλáς Μ.ΕΠΕ.

Τηλ: + 30 (0) 210 8930 100

Sverige

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Latvija

Gilead Sciences Poland Sp. z o.o.

Tel.: + 48 (0) 22 262 8702

United Kingdom (Northern Ireland)

Gilead Sciences Ireland UC

Tel: + 44 (0) 8000 113 700

Date of Last Revision of this Leaflet: <{MM/AAAA}> <{mes AAAA}>.

This medicinal product has been authorized with a "conditional approval". This approval mechanism means that more information on this medicinal product is expected.

The European Medicines Agency will review the new information on this medicinal product at least once a year, and this leaflet will be updated as necessary.

  1. Step-by-Step Injection Guide

Before using Hepcludex, you must first read sections 1-6 of this leaflet.

Before starting treatment with this medication at home, your doctor or nurse will teach you how to prepare and inject Hepcludex. This guide indicates how you should inject the medication yourself. Consult your doctor or nurse if there is anything you do not understand, if you have any questions, or if you need more information or help. Take the time to prepare and inject Hepcludex carefully.

Injection Sites

Abdomen

Upper Thigh

To reduce reactions at the injection site, you can change the injection site of bulevirtida regularly.

Do not injectbulevirtida into the following areas: knee, groin, lower or inner buttocks, directly into a blood vessel, around the navel, into scar tissue, hematomas, moles, a surgical scar, tattoos, or burns, or where an injection site reaction has occurred.

Male torso with shaded areas indicating injection sites in the abdominal and upper lumbar regions

Human body showing recommended injection areas on the thighs highlighted in blue with diagonal lines

Refrigerator with blue shelves showing medication vials and a carton of milk at the bottom indicating a temperature of 2-8°C

Hand holding a medication vial and gently rotating it between the thumb and index finger

Faucet with running water pouring over an outstretched hand in a light blue sink

Hands holding a medication vial and a syringe with a needle, along with an open package and a disinfectant wipe

1A

Storage

1B

Mixing Dose

1C

Washing Hands

1D

Cleaning the Vial

The bulevirtida vials should be stored in the original packaging in the refrigerator (between 2 and 8 °C) to protect bulevirtida from light.

Reconstituted bulevirtida should be used immediately.

The following instructions are for dissolving a single dose.

Wash your hands thoroughly with soap and warm water and dry them with a clean towel.

Once your hands are clean, do not touch anything other than the medication, auxiliary materials, and the area surrounding the injection site.

Rub the top of the vial with a new cotton ball soaked in alcohol and let it air dry.

If you touch the rubber stopper after cleaning, clean it again with another cotton ball soaked in alcohol.

Hand holding a syringe drawing liquid from a vial labeled as WATER with a transparent needle

Syringe needle drawing liquid from a transparent vial with a gray cap held by a gloved hand

Hand holding a medication vial with the thumb and index finger preparing for injection

2A

Withdrawing Sterile Water

2B

Injecting Sterile Water into the Powder

2C

Gently Mixing Bulevirtida

Take the syringe. Place the longest needle on it.

Important!Make sure the capped needle is securely attached by gently pressing and twisting it clockwise.

Remove the plastic cap.

Open the sterile water for injectable preparations. Insert the needle into the vial and gently invert the water vial. Make sure the needle tip is always below the surface of the water to prevent air bubbles from entering the syringe.

Slowly pull the plunger until you have 1.0 cc/ml of sterile water inside the syringe. Carefully remove the needle and syringe from the vial.

Gently tap the bulevirtida vial to loosen the powder. Insert the needle with sterile water into the bulevirtida vial at an angle.

Slowly inject the sterile water so that it trickles down the side of the vial onto the bulevirtida powder.

Gently tap the bulevirtida vial with your fingertips for 10 seconds to start dissolving the powder. Then, gently rotate the bulevirtida vial between your hands to mix it completely.

Make sure there is no bulevirtida powder stuck to the sides of the vial.

Important!Do not shake the bulevirtida vial. If you shake it, foam will form, and the medication will take much longer to dissolve.

Transparent medication vial with liquid and a red clock indicating waiting or preparation time

Transparent medication vial with a gray cap and a blue circle with a checkmark next to it

2D

Inspecting Bulevirtida

2E

Bulevirtida Ready for Injection

Once the powder starts to dissolve, let it sit, and it will completely dissolve. After tapping, it may take up to 3 minutes to dissolve.

When it is fully mixed, the bulevirtida solution should be clear.

Important!Fully dissolved bulevirtida should be clear and free of foam.

If the bulevirtida solution is foamy or yellowish, let it dissolve for a longer time.

If you see bubbles, gently tap the vial until they disappear.

If you notice particles in the bulevirtida solution once it is fully dissolved, do not use that vial. Consult the doctor or pharmacist who supplied it to you.

Hand holding a syringe injecting medication into a transparent vial with a light gray cap

Medication vial with a gray adapter connected to a transparent hypodermic needle

Gloved hands holding a syringe filled with clear liquid and a transparent glass ampoule

Hand holding a syringe with a needle pointing towards a sharps container with an arrow indicating direction

3A

Inserting the Needle into the Vial

3B

Withdrawing Bulevirtida

3C

Completing Preparation

3D

Changing and Discarding the Needle

Take the syringe.

Insert the needle into the bulevirtida liquid vial.

Gently invert the vial. Make sure the needle tip is always below the surface of the bulevirtida solution so that no air bubbles enter the syringe. Slowly pull the plunger to draw 1.0 cc/ml of bulevirtida into the syringe.

Gently tap or shake the syringe and push/pull the plunger to eliminate any additional air and bubbles.

To ensure you end up with 1.0 cc/ml of bulevirtida in the syringe, you may need to pull the plunger past the 1.0 cc/ml mark.

Carefully remove the needle and syringe from the vial.

Remove the longer needle from the syringe and discard it properly so that no one can get hurt.

Important!Do not put the plastic cap back on the needle.

Hand holding a syringe with a needle inserted into a skin fold lifted with the thumb and index finger

Hand applying a light blue adhesive patch over the skin on the upper abdomen of a person

Hand applying pressure on a shaded area on the upper arm covered with light blue fabric

Syringe with a needle inserted into the skin at a 45-degree angle, with an arrow indicating the angle of insertion and visible subcutaneous tissue

3E

Inserting the Needle for Injection

3F

Choosing the Injection Site

3G

Preparing the Injection Site

3H

Injecting Bulevirtida

Place the shorter needle on the syringe.

Important!Make sure the capped needle is securely attached by gently pressing and twisting it clockwise.

Remove the plastic cap.

Choose a different site from the one you used for your last injection. Clean the injection site with a new cotton ball soaked in alcohol.

Start in the center, apply pressure, and clean in a circular motion outward.

Important!Let the area air dry. Prepare the bulevirtida vial. Clean the top of the bulevirtida vial again with a new cotton ball soaked in alcohol.

Let it air dry.

Pinch the skin around the injection site.

Puncture the skin at a 45-degree angle. Most of the needle should be inserted.

Slowly push the plunger all the way to inject bulevirtida.

Remove the needle from the skin.

Remove the needle from the syringe and discard both properly so that no one can get hurt (see 3D).

Alternatives to HEPCLUDEX 2 mg POWDER FOR INJECTABLE SOLUTION in other countries

The best alternatives with the same active ingredient and therapeutic effect.

Alternative to HEPCLUDEX 2 mg POWDER FOR INJECTABLE SOLUTION in Ukraine

Dosage form: suppositories, 5 suppositories of 3 g in a blister
Manufacturer: TOV "NVK "Ekofarm
Prescription required
Dosage form: drops, 10 ml, 30 ml, 50 ml in a glass bottle
Manufacturer: TOV "NVK "Ekofarm
Prescription required
Dosage form: tablets, 0.02 g
Manufacturer: PrAT "Tehnolog
Prescription not required
Dosage form: tablets, tablets 20mg

Online doctors for HEPCLUDEX 2 mg POWDER FOR INJECTABLE SOLUTION

Discuss dosage, side effects, interactions, contraindications, and prescription renewal for HEPCLUDEX 2 mg POWDER FOR INJECTABLE SOLUTION – subject to medical assessment and local rules.

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe